Welcome to LookChem.com Sign In|Join Free
  • or
2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazole-5-carbaldehyde is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1127329-22-9

Post Buying Request

1127329-22-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1127329-22-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1127329-22-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,2,7,3,2 and 9 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1127329-22:
(9*1)+(8*1)+(7*2)+(6*7)+(5*3)+(4*2)+(3*9)+(2*2)+(1*2)=129
129 % 10 = 9
So 1127329-22-9 is a valid CAS Registry Number.

1127329-22-9Downstream Products

1127329-22-9Relevant academic research and scientific papers

INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY

-

, (2009/10/22)

This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.

INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY

-

Page/Page column 90; 92, (2009/04/25)

The invention relates to compounds of Formula (I) and their use for inhibiting protein tyrosine kinase activity In Formula (I), the group M is thieno[3,2,b]pyridinyl as shown, and the group D is a ring or ring system, and the groups Z, Ar, and G are as defined herein The invention relates particularly to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling The invention also provides compositions and methods for treating cell proliferative diseases and conditions, such as cancer, and for treating ophthalmic diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR)

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1127329-22-9